A Health Economic Model to Assess the Long-Term Effects and Cost-Effectiveness of Orlistat in Obese Type 2 Diabetic Patients
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
OBJECTIVES—Obesity is a common condition in type 2 diabetic patients. Treating obesity may enhance hypoglycemic treatment and contribute to the reduction of long-term microvascular and macrovascular complications. Orlistat reduces cardiovascular risk factors in obese type 2 diabetic patients. The objectives of this study were to estimate the long-term clinical consequences of this weight loss and the resulting cost-effectiveness of treating obese type 2 diabetic patients with orlistat. RESEARCH DESIGN AND METHODS—A Markov model was developed to predict, over a 10-year period, the complication rates and mortality with and without a 2-year orlistat treatment, assuming a 5-year catch-up period after treatment. A stepwise approach was used to obtain the clinical data. First, the impact of weight loss with orlistat on HbA1c, blood pressure, and cholesterol was assessed; then, the impact on mortality and micro- and macrovascular complications of decreasing these risk factors was applied. Four subgroups were studied based on the presence of risk factors. RESULTS—Cost-effectiveness varies between 3,462 Euro/life-year gained (LYG) for obese diabetic patients with hypertension and hypercholesterolemia and 19,986 Euro/LYG for obese diabetic patients without other risk factors. The latter result is not robust according to sensitivity analyses. CONCLUSIONS—Our results suggest that orlistat is cost-effective in the management of obese type 2 diabetic patients, especially in those with the presence of hypercholesterolemia and/or hypertension. Evidence on longer-term benefits of orlistat (>2 years) will be of importance for future decision-making.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adler, A. I. (2000) · BMJ · doi:10.1136/bmj.321.7258.412 · Cited by 2,133
The effect of age on the association between body-mass index and mortality
Stevens, J., Cai, J., Pamuk, E. R., Williamson, D. F., Thun, M. J., & Wood, J. L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801013380101 · Cited by 1,611
Hollander, P. A., Elbein, S. C., Hirsch, I. B., Kelley, D., McGill, J., Taylor, T., Weiss, S. R., Crockett, S. E., Kaplan, R. A., Comstock, J., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1288 · Cited by 654
Coronary Heart Disease Incidence in NIDDM Patients In The Helsinki Heart Study
Koskinen, P., Mänttäri, M., Manninen, V., Huttunen, J. K., Heinonen, O. P., & Frick, M. H. (1992) · Diabetes Care · doi:10.2337/diacare.15.7.820 · Cited by 509
The Cost–Utility of Screening for Depression in Primary Care
Valenstein, M., Vijan, S., Zeber, J. E., Boehm, K., & Buttar, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-5-200103060-00007 · Cited by 268
HDL-Cholesterol, Total Cholesterol, and the Risk of Stroke in Middle-Aged British Men
Wannamethee, S. G., Shaper, A. G., & Ebrahim, S. (2000) · Stroke · doi:10.1161/01.str.31.8.1882 · Cited by 220
Lifetime health and economic benefits of weight loss among obese persons.
Oster, G., Thompson, D., Edelsberg, J., Bird, A. P., & Colditz, G. A. (1999) · American Journal of Public Health · doi:10.2105/ajph.89.10.1536 · Cited by 193
The cost-effectiveness of screening for type 2 diabetes
The CDC Diabetes Cost-Effectiveness Study Group (1998) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.280.20.1757 · Cited by 175
Cited by
Kelley, D. E., Bray, G. A., Pi-Sunyer, F. X., Klein, S., Hill, J., Miles, J., & Hollander, P. (2002) · Diabetes Care · doi:10.2337/diacare.25.6.1033 · Cited by 314
“(32) conducted a cost-benefit analysis of using orlistat in the treatment of type 2 diabetes, based upon a Markov model, using the previously published data of Hollander et al.”
MethodIs There a Role for ??-Glucosidase Inhibitors in the Prevention of Type 2 Diabetes Mellitus?
Scheen, A. J. (2003) · Drugs · doi:10.2165/00003495-200363100-00002 · Cited by 242
A systematic review of the clinical effectiveness of orlistat used for the management of obesity
O'Meara, S., Riemsma, R., Shirran, L., Mather, L., & Ter Riet, G. (2004) · Obesity Reviews · doi:10.1111/j.1467-789x.2004.00125.x · Cited by 103
“Another economic evaluation used a Markov model to estimate the cost-effectiveness of using orlistat to treat obese patients with type 2 diabetes (52).”
MethodEconomic Outcomes of the Obese Patient
Wolf, A. M. (2002) · Obesity Research · doi:10.1038/oby.2002.191 · Cited by 46
“They reported that Orlistat is a cost-effective therapeutic lCE ratio range: 3462 euros/life-year gained (LYG) when patients had type 2 diabetes, hypercholesterolemia, and hypertension; 7407 euros/LYG with hypercholesterolemia and type 2 diabetes; 7388 euros/LYG with hypertension and type 2 diabetes; 19,986 euros/LYG…”
BackgroundRuof, J., Golay, A., Berne, C., Collin, C., Lentz, J., & Maetzel, A. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0802925 · Cited by 40
Metadata
- Authors
- Lamotte, M., Annemans, L., Lefever, A., Nechelput, M., & Masure, J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2002-02-01
- Volume
- 25
- Issue
- 2
- Pages
- 303-308
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2169717006
- Cited by
- 66
- References
- 8
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.